On October 21, 2024, at the FDA White Oak Campus,  CAPNOS CEO, Brendan Wang, spoke about the critical need for increased research and representation in addressing the behavioral dependence that often accompanies vaping addiction. Wang’s message was clear: To address the FDA’s goals for advancing smoking cessation innovation, we need to go beyond conventional nicotine replacement therapies (NRTs) to better understand the sensory dependencies that many people struggle with. 

In the video below, Wang discusses his journey of quitting vaping after years of dependence. Drawing from this experience, CAPNOS created a new device category that focuses on simulating the sensory cues of vaping without nicotine, smoke, or tobacco. As the devices are not tobacco, medical, or food products, CAPNOS can be largely accessible to the public so that anyone can be “Zeroing” anytime, anywhere. 

Since launching in 2022, over 70,000 devices have reached consumers in 70 countries worldwide. CAPNOS is committed to sustainability and accessibility to make an impact on academic and healthcare institutions. CAPNOS has also worked with colleagues at academic medical institutions with a grant application currently under review to evaluate CAPNOS devices in a human laboratory setting. 

Wang's call to action for regulators, retailers, and health insurers is to join the efforts to achieve harm reduction and lower vaping or smoking rates by supporting innovative methods through research, pilot programs with CAPNOS devices, and inviting conversational representation.

Watch the full presentation in the video below to learn more about how CAPNOS is revolutionizing the approach to vaping cessation.